4.5 Article

2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheterisation: the ARCTIC randomised controlled feasibility trial

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/archdischild-2023-325871

关键词

Infectious Disease Medicine; Microbiology; Neonatology; Sepsis

向作者/读者索取更多资源

This study aimed to evaluate the best antiseptic for skin disinfection before percutaneous central venous catheter (PCVC) insertion in preterm neonates. It found that both 2% chlorhexidine gluconate-70% isopropyl alcohol and 2% chlorhexidine gluconate-aqueous were safe to use. However, conducting a large-scale randomized controlled trial may be challenging due to the very low catheter colonization rate.
Objective Catheter-related sepsis (CRS) is a major complication with significant morbidity and mortality. Evidence is lacking regarding the most appropriate antiseptic for skin disinfection before percutaneous central venous catheter (PCVC) insertion in preterm neonates. To inform the feasibility and design of a definitive randomised controlled trial (RCT) of two antiseptic formulations, we conducted the Antiseptic Randomised Controlled Trial for Insertion of Catheters (ARCTIC) feasibility study to assess catheter colonisation, sepsis, and skin morbidity.Design Feasibility RCT.Setting Two UK tertiary-level neonatal intensive care units.Patients Preterm infants born <34 weeks' gestation scheduled to undergo PCVC insertion.Interventions Skin disinfection with either 2% chlorhexidine gluconate (CHG)-aqueous or 2% CHG-70% isopropyl alcohol (IPA) before PCVC insertion and at removal.Primary outcome Proportion in the 2% CHG-70% IPA arm with a colonised catheter at removal.Main feasibility outcomes Rates of: (1) CRS, catheter-associated sepsis (CAS), and CRS/CAS per 1,000 PCVC days; (2) recruitment and retention; (3) data completeness.Safety outcomes Daily skin morbidity scores recorded from catheter insertion until 48 hours post-removal.Results 116 babies were randomised. Primary outcome incidence was 4.1% (95% confidence interval: 0.9% to 11.5%). Overall catheter colonisation rate was 5.2% (5/97); CRS 2.3/1000 catheter days; CAS 14.8/1000 catheter days. Recruitment, retention and data completeness were good. No major antiseptic-related skin injury was reported.Conclusions A definitive comparative efficacy trial is feasible, but the very low catheter colonisation rate would make a large-scale RCT challenging due to the very large sample size required. ARCTIC provides preliminary reassurance supporting potential safe use of 2% CHG-70% IPA and 2% CHG-aqueous in preterm neonates.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据